Login to Your Account



Maxygen Lands $170M Preclinical Deal with Astellas

By Trista Morrison


Monday, September 22, 2008
Less than three months after selling preclinical hemophilia drug MAXY-VII to Bayer HealthCare in a deal worth up to $120 million, Maxygen Inc. is at it again. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription